Search

Explains that the hereditary neurodegenerative disease spinal muscular atrophy (SMA) with childhood onset is a common cause of infant mortality, and is characterized by selective loss of spinal cord motor neurons leading to muscle atrophy. Mutation in the survival motor neuron (SMN) gene; SMN protein implicated in diverse nuclear processes including splicing, ribosome formation, and gene transcription.

Abstract: Knee osteoarthritis (OA) is a common degenerative joint disorder and a major cause of pain and disability. The hypothesis tested in this study was that the passion fruit peel extract (PFP), a flavonoid-rich dietary supplement, would reduce symptoms due to knee OA. Thirty-three OA patients were enrolled in a randomized, double-blind, placebo-controlled trial with parallel-group design. Patients received either placebo or PFP pills (150 mg, daily) in a double-blinded fashion for 2 months. The OA clinical symptoms were evaluated monthly with Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index. In the PFP group, there was a significant improvement in total WOMAC score and WOMAC subscale score of physical function after 30 days and pain after 60 days. At 60 days, reductions of 18.6%, 18%, 19.6%, and 19.2% in pain, stiffness, physical function, and composite WOMAC score, respectively, were self-reported in the PFP group. Whereas, in the placebo group, the self-reported WOMAC scores increased in every category. The results of this study show that PFP substantially alleviated osteoarthritis symptoms. This beneficial effect of PFP may be due to its antioxidant and antiinflammatory properties. [ABSTRACT FROM AUTHOR]

Abstract: Knee osteoarthritis (OA) is a common degenerative joint disorder and a major cause of pain and disability. The purpose of this study was to investigate the potential effect of Pycnogenol (Horphag Research, Ltd, Geneva, Switzerland), a flavonoid-rich dietary supplement, on the symptoms of knee OA. Thirty-seven osteoarthritic patients were enrolled in a randomized, double-blind, placebo-controlled trial with parallel-group design. Patients received either placebo or Pycnogenol pills (50 mg, three times daily) in a blinded fashion for 3 months. Osteoarthritis clinical symptoms were evaluated monthly with Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index. Nonsteroidal anti-inflammatory drugs (NSAIDs) or selective cyclooxygenase 2 (COX-2) inhibitors usage was also assessed. In the Pycnogenol group, there was a significant improvement in total WOMAC score and WOMAC subscale score of pain and physical function at 60 and 90 days of treatment. At 90 days, significant reduction of 43%, 35%, 52%, and 49% in self-reported pain, stiffness, physical function, and composite WOMAC score, respectively, were reported in Pycnogenol group, whereas the placebo group showed no significant changes. The dosage and frequency of NSAIDs or COX-2 inhibitors usage were increased in placebo group, which were significantly less in Pycnogenol group. The results of this study indicate the efficacy of Pycnogenol in alleviating osteoarthritis symptoms and reducing the need for NSAIDs or COX-2 inhibitors administration. This beneficial effect of Pycnogenol might be due to its antioxidant and anti-inflammatory properties. Further research is warranted to determine the underlying mechanism associated with this apparent effect. [Copyright &y& Elsevier]